Moreover, SV2A can be used to further identify the possible mechanisms underlying synaptic dysfunction and loss in AD, and it can also be used as a new target for the early diagnosis and treatment of AD (Stockburger et al., 2016). This evidence concerns the gene SV2A and Alzheimer disease.